Precision for Value will be at the annual AMCP Managed Care & Specialty Pharmacy Meeting in San Francisco which will be held April 19-22 at the Moscone West convention center in San Francisco, California.
The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.
A pharmaceutical manufacturer was preparing to launch 2 biosimilars with autoimmune disease indications across 6 European markets. With several access challenges for both products anticipated, this case study shares our approach to the assessment of likely access conditions and price potentials at launch, as well as the evidence generation needed to improve those scenarios across markets. The findings were critical to informing the development of a pricing strategy for both biosimilars.
Rick Lifsitz and Larry Blandford discuss if higher prices really translate into greater perceived therapeutic effectiveness in a new commentary for Journal of Clinical Pathways
Dan Renick comments on the burden of out-of-pocket patient costs for specialty medications in PM360.
Jeremy Schafer examines payer reaction to FDA warnings in Pharmaceutical Commerce.
Precision for Value is excited to be leading a presentation at the upcoming AMCP Partnership Forum, FDAMA 114: Improving the Exchange of Pharmacoeconomic Data, to be held March 1-2, 2016 at the Marriott Marquis in Washington, DC.
Precision will be sponsoring, presenting and exhibiting at the World Pharma Pricing & Market Access Congress event in London, England.
Breakout Session, February 9th (two concurrent): Opposing Influences of Evidence and Market Forces in Pharmaceutical Pricing and Payer Net Cost
Larry Blandford – Senior Vice President & Managing Partner, Precision for Value
Steve Carter – Vice President, Pricing and Market Access, Precision for Value
This session will outline the process often used by manufacturers to establish a price for a product and compare that to how payers assess how that cost impacts the perception of value. The presenters will outline how clinical and economic evidence, research, and market forces can shift price points through launch preparation. New research on how payers perceive a product based on price will be unveiled along with implications across different benefits plans, such as Medicare Part D and employer-funded programs. Lastly, evolving and future methods for alignment between these stakeholders will be shared.
Precision’s Lakdawalla on the BBC: ‘You can’t just ban Twinkies’
Precision’s Darius Lakdawalla was recently interviewed for the BBC’s Business Daily program, discussing the trend to ban large size sodas and other recent anti-junk food measures.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
